Analysis of Single Nucleotide Polymorphisms in the Melanocortin-4 Receptor Promoter in Infantile Spasms

Abstract

Objectives: Infantile spasms is a severe epileptic encephalopathy of infancy. ACTH that ameliorates infantile spasms might act through activating the central melanocortin-4 receptor (MC4R) to suppress excessive production of corticotrophin-releasing hormone (CRH). This study aimed to elucidate an association between the genetic variants of the MC4R gene and infantile spasms.

Methods: The study population comprised 96 patients with infantile spasms and 118 controls. All subjects were screened for variations in the promoter and coding region of the MC4R gene using a direct sequencing method. ATCH responses in patients carrying different genotypes were also assessed.

Results: The distributions of genotypes and alleles of rs11872992 in the MC4R promoter were significantly different between cases and controls. The frequencies of heterozygous carriers (TC genotype) were significantly lower in cases (10%) than in controls (27%) (p=0.003). The distributions of rs11872992 TC and CC genotypes were significantly different between ACTH responders and non-responders (OR, 0.14; 95% C.I, 0.03-0.69; p=0.007). The T-allele carriers (83.3%) had a higher responsiveness to ACTH than non-carriers (41.7%).

Conclusions: The present study shows that genetic variants in the MC4R promoter are associated with the development of infantile spasms. The rs11872992 polymorphism influences ACTH treatment responses in patients with infantile spasms.

Key words

infantile spasms - melanocortin-4 receptor gene - genetic polymorphism - association

References

• 1 Baram TZ. Pathophysiology of massive infantile spasms: perspective on the putative role of the brain adrenal axis.  Ann Neurol. 1993;  33 231-236
• 2 Baram TZ. Treatment of infantile spasms: the ideal and the mundane.  Epilepsia. 2003;  44 993-994
• 3 Baram TZ, Hatalski CG. Neuropeptide-mediated excitability: a key triggering mechanism for seizure generation in the developing brain.  Trends Neurosci. 1998;  21 471-476
• 4 Baram TZ, Mitchell WG, Hanson RA, Snead 3rd OC, Horton EJ. Cerebrospinal fluid corticotropin and cortisol are reduced in infantile spasms.  Pediatr Neurol. 1995;  13 108-110
• 5 Baram TZ, Mitchell WG, Snead 3rd OC, Horton EJ, Saito M. Brain adrenal axis hormones are altered in the CSF of infants with massive infantile spasms.  Neurology. 1992;  42 1171-1175
• 6 Baram TZ, Mitchell WG, Tournay A, Snead OC, Hanson RA, Horton EJ. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study.  Pediatrics. 1996;  97 375-379
• 7 Bienvenu T, Poirier K, Friocourt G, Bahi N, Beaumout D, Fauchereau F. et al . a novel Prd-class-homeobox gene highly expressed in the telencephalon, is mutated in X-linked mental retardation.  Hum Mol Genet. 2002;  11 981-991
• 8 Blondet A, Gout J, Durand P, Begeot M, Naville D. Expression of the human melanocortin-4 receptor gene is controlled by several members of the Sp transcription factor family.  J Mol Endocrinol. 2005;  34 317-329
• 9 Brunson KL, Avishai-Eliner S, Baram TZ. ACTH treatment of infantile spasms: mechanisms of its effects in modulation of neuronal excitability.  Int Rev Neurobiol. 2002;  49 185-197
• 10 Brunson KL, Eghbal-Ahmadi M, Baram TZ. How do the many etiologies of West syndrome lead to excitability and seizures? The corticotropin releasing hormone excess hypothesis.  Brain Dev. 2001;  23 533-538
• 11 Brunson KL, Eghbal-Ahmadi M, Bender R, Chen Y, Baram TZ. Long-term, progressive hippocampal cell loss and dysfunction induced by early-life administration of corticotropin-releasing hormone reproduce the effects of early-life stress.  Proc Natl Acad Sci USA. 2001;  98 8856-8861
• 12 Brunson KL, Khan N, Eghbal-Ahmadi M, Baram TZ. Corticotropin (ACTH) acts directly on amygdala neurons to down-regulate corticotropin-releasing hormone gene expression.  Ann Neurol. 2001;  49 304-312
• 13 Cheadle JP, Reeve MP, Sampson JR, Kwiatkowski DJ. Molecular genetic advances in tuberous sclerosis.  Hum Genet. 2000;  107 97-114
• 14 Cone RD, Lu D, Koppula S, Vage DI, Klungland H, Boston B. et al . The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation.  Recent Prog Horm Res. 1996;  51 287-317
• 15 Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J. et al . Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs.  Am J Hum Genet. 2001;  68 64-80
• 16 Wied D De, Croiset G. Stress modulation of learning and memory processes.  Methods Achiev Exp Pathol. 1991;  15 167-199
• 17 Wied D De, Jolles J. Neuropeptides derived from pro-opiocortin: behavioral, physiological, and neurochemical effects.  Physiol Rev. 1982;  62 976-1059
• 18 Elias LL, Clark AJ. The expression of the ACTH receptor.  Braz J Med Biol Res. 2000;  33 1245-1248
• 19 Elias LL, Huebner A, Pullinger GD, Mirtella A, Clark AJ. Functional characterization of naturally occurring mutations of the human adreno- corticotropin receptor: poor correlation of phenotype and genotype.  J Clin Endocrinol Metab. 1999;  84 2766-2770
• 20 Engel Jr J. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology.  Epilepsia. 2001;  42 796-803
• 21 Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of melano-cortinergic neurons in feeding and the agouti obesity syndrome.  Nature. 1997;  385 165-168
• 22 Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O’Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene.  N Engl J Med. 2003;  348 1085-1095
• 23 Feng JD, Dao T, Lipton JM. Effects of preoptic microinjections of alpha-MSH on fever and normal temperature control in rabbits.  Brain Res Bull. 1987;  18 473-477
• 24 Frost Jr JD, Hrachovy RA. Pathogenesis of infantile spasms: a model based on developmental desynchronization.  J Clin Neurophysiol. 2005;  22 25-36
• 25 Gantz I, Miwa H, Konda Y, Shimoto Y, Tashiro T, Watson SJ. et al . Molecular cloning, expression, and gene localization of a fourth melanocortin receptor.  J Biol Chem. 1993;  268 15174-15179
• 26 Gee CE, Chen CL, Roberts JL, Thompson R, Watson SJ. Identification of proopiomelanocortin neurones in rat hypothalamus by in situ cDNA-mRNA hybridization.  Nature. 1983;  306 374-376
• 27 Getting SJ. Targeting melanocortin receptors as potential novel therapeutics.  Pharmacol Ther. 2006;  111 1-15
• 28 Guerrini RR. Epileptogenic brain malformations: clinical presentation, malformative patterns and indications for genetic testing.  Seizure. 2001;  10 532-543
• 29 Gutierrez-Delicado E, Serratosa JM. Genetics of the epilepsies.  Curr Opin Neurol. 2004;  17 147-153
• 30 Hollrigel GS, Chen K, Baram TZ, Soltesz I. The pro-convulsant actions of corticotropin-releasing hormone in the hippocampus of infant rats.  Neuroscience. 1998;  84 71-79
• 31 Ito M. Extremely low-dose ACTH therapy for West syndrome in Japan.  Brain Dev. 2001;  23 635-641
• 32 Jaseja HA. Plausible explanation for superiority of adreno-cortico-trophic hormone (ACTH) over oral corticosteroids in management of infantile spasms (West syndrome).  Med Hypotheses. 2006;  67 721-724
• 33 Kalscheuer VM, Tao J, Donnelly A, Hollway G, Schwinger E, Kübart S, Menzel C. et al . Disruption of the serine/threonine kinase 9 gene causes severe X-linked infantile spasms and mental retardation.  Am J Hum Genet. 2003;  72 1401-1411
• 34 Kivity S, Lerman P, Ariel R, Danziger Y, Mimouni M, Shinnar S. Long-term cognitive outcomes of a cohort of children with cryptogenic infantile spasms treated with high-dose adrenocorticotropic hormone.  Epilepsia. 2004;  45 255-262
• 35 Li SJ, Varga K, Archer P, Hruby VJ, Sharma SD, Kesterson RA. et al . Melanocortin antagonists define two distinct pathways of cardiovascular control by alpha- and gamma-melanocyte-stimulating hormones.  J Neurosci. 1996;  16 5182-5188
• 36 Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW. et al . The United Kingdom infantile spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial.  Lancet. 2004;  364 1773-1778
• 37 Lux AL, Osborne JP. A proposal for case definitions and outcome measures in studies of infantile spasms and West syndrome: consensus statement of the West Delphi group.  Epilepsia. 2004;  45 1416-1428
• 38 Mackay MT, Weiss SK, Adams-Webber T, Ashwal S, Stephens D, Ballaban-Gill K. et al . Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society.  Neurology. 2004;  62 1668-1681
• 39 Mountjoy KG, Mortrud MT, Low MJ, Simerly RB, Cone RD. Localiza-tion of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain.  Mol Endocrinol. 1994;  8 1298-1308
• 40 Mountjoy KG, Robbins LS, Mortrud MT, Cone RD. The cloning of a family of genes that encode the melanocortin receptors.  Science. 1992;  257 1248-1251
• 41 Nagamitsu S, Matsuishi T, Yamashita Y, Shimizu T, Iwanaga R, Murakami Y. et al . Decreased cerebrospinal fluid levels of beta-endorphin and ACTH in children with infantile spasms.  J Neural Transm. 2001;  108 363-371
• 42 Nalin A, Facchinetti F, Galli V, Petraglia F, Storchi R, Genazzani AR. Reduced ACTH content in cerebrospinal fluid of children affected by cryptogenic infantile spasms with hypsarrhythmia.  Epilepsia. 1985;  26 446-449
• 43 Naville D, Jaillard C, Barjhoux L, Durand P, Bégeot M. Genomic structure and promoter characterization of the human ACTH receptor gene.  Biochem Biophys Res Commun. 1997;  230 7-12
• 44 Nijenhuis WA, Garner KM, Rozen RJ van, Adan RA. Poor cell surface expression of human melanocortin-4 receptor mutations associated with obesity.  J Biol Chem. 2003;  278 22939-22945
• 45 O’Callaghan FJ, Harris T, Joinson C, Bolton P, Noakes M, Presdee D. et al . The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex.  Arch Dis Child. 2004;  89 530-533
• 46 Penhoat A, Naville D, El Mourabit H, Buronfosse A, Berberoglu M, Ocal G. et al . Functional relationships between three novel homozygous mutations in the ACTH receptor gene and familial glucocorticoid deficiency.  J Mol Med. 2002;  8 406-411
• 47 Riikonen R. Infantile spasms: therapy and outcome.  J Child Neurol. 2004;  19 401-404
• 48 Riikonen RS, Söderström S, Vanhala R, Ebendal T, Lindholm DB. West syndrome: cerebrospinal fluid nerve growth factor and effect of ACTH.  Pediatr Neurol. 1997;  17 224-229
• 49 Shinyama H, Masuzaki H, Fang H, Flier JS. Regulation of melanocortin-4 receptor signaling: agonist-mediated desensitization and internalization.  Endocrinology. 2003;  144 1301-1314
• 50 Slawik M, Reisch N, Zwermann O, Maser-Gluth C, Stahl M, Klink A. et al . Characterization of an adrenocorticotropin (ACTH) receptor promoter polymorphism leading to decreased adrenal responsiveness to ACTH.  J Clin Endocrinol Metab. 2004;  89 3131-3137
• 51 Tao YX, Segaloff DL. Functional analyses of melanocortin-4 receptor mutations identified from patients with binge eating disorder and nonobese or obese subjects.  J Clin Endocrinol Metab. 2005;  90 5632-5638
• 52 Valli-Jaakola K, Lipsanen-Nyman M, Oksanen L, Hollenberg AN, Kontula K, Bjørbaek C. et al . Identification and characterization of melanocortin-4 receptor gene mutations in morbidly obese finnish children and adults.  J Clin Endocrinol Metab. 2004;  89 940-945
• 53 Vanhatalo S, Riikonen R. Nitric oxide metabolites, nitrates and nitrites in the cerebrospinal fluid in children with west syndrome.  Epilepsy Res. 2001;  46 3-13
• 54 Voisey J, Carroll L, Daal A van. Melanocortins and their receptors and antagonists.  Curr Drug Targets. 2003;  4 586-597
• 55 Yanagaki S, Oguni H, Hayashi K, Imai K, Funatuka M, Tanaka T. et al . A comparative study of high-dose and low-dose ACTH therapy for West syndrome. Brain & development.  Brain Dev. 1999;  21 461-467
• 56 Yeo GS, Lank EJ, Farooqi IS, Keogh J, Challis BG, O’Rahilly S. Mutations in the human melanocortin-4 receptor gene associated with severe familial obesity disrupts receptor function through multiple molecular mechanisms.  Hum Mol Genet. 2003;  12 561-574

Correspondence